{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:18:51Z","timestamp":1784204331184,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.heliyon.2023.e23206","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T21:18:49Z","timestamp":1701551929000},"page":"e23206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficiency of B-RAF-\/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-4786","authenticated-orcid":false,"given":"Reinhard","family":"B\u00fcttner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-3617","authenticated-orcid":false,"given":"Sibel Elif","family":"G\u00fcltekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Heydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-1812","authenticated-orcid":false,"given":"Lucia","family":"Nogova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7141-7535","authenticated-orcid":false,"given":"Sonja","family":"Meemboor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Aziz-Heiloun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e23206_bib1","unstructured":"world, P.b.a.a.e.C.f.a.t., WHO classification of tumours editorial board. Head and neck tumors. Lyonia: International Agency for Research on Cancer 2022. 5th ed.; vol. 9."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2023.e23206_bib2","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.4103\/0975-7406.155891","article-title":"Ameloblastoma","volume":"7","author":"Masthan","year":"2015","journal-title":"J Pharm Bioallied Sci"},{"issue":"21","key":"10.1016\/j.heliyon.2023.e23206_bib3","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1158\/1078-0432.CCR-14-1069","article-title":"Activating FGFR2-RAS-BRAF mutations in ameloblastoma","volume":"20","author":"Brown","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1186\/s12885-018-4802-y","article-title":"Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation","volume":"18","author":"Fernandes","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw190","article-title":"Durable treatment of ameloblastoma with single agent BRAFi Re: clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma","volume":"109","author":"Faden","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23206_bib6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00428-018-2305-5","article-title":"The landscape of genetic alterations in ameloblastomas relates to clinical features","volume":"472","author":"G\u00fcltekin","year":"2018","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12070-012-0599-1","article-title":"Wide surgical excision with split rib graft reconstruction of mandible for ameloblastoma; our 10 year experience","volume":"65","author":"Ahmad","year":"2013","journal-title":"Indian J. Otolaryngol. Head Neck Surg."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1563\/AAID-JOI-D-13-00003","article-title":"Report of multidisciplinary treatment of an extensive mandibular ameloblastoma with free iliac crest bone flap, dental implants, and acellular dermal matrix graft","volume":"41","author":"Askin","year":"2015","journal-title":"J. Oral Implantol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23206_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23206_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12032-023-01993-z","article-title":"BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature","volume":"40","author":"Ebeling","year":"2023","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23206_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.surge.2020.06.009","article-title":"Ameloblastoma: a succinct review of the classification, genetic understanding and novel molecular targeted therapies","volume":"19","author":"Shi","year":"2021","journal-title":"Surgeon"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23206_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/term.3254","article-title":"Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration","volume":"15","author":"Hirschhorn","year":"2021","journal-title":"J Tissue Eng Regen Med"},{"key":"10.1016\/j.heliyon.2023.e23206_bib14","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fonc.2019.01204","article-title":"Enabling precision medicine for rare head and neck tumors: the example of BRAF\/MEK targeting in patients with metastatic ameloblastoma","volume":"9","author":"Brunet","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/jnci\/dju378","article-title":"Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma","volume":"107","author":"Kaye","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib16","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.oooo.2015.12.016","article-title":"BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response","volume":"122","author":"Tan","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23206_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13256-019-2140-6","article-title":"Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report","volume":"13","author":"Broudic-Guibert","year":"2019","journal-title":"J. Med. Case Rep."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023104142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023104142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:02:33Z","timestamp":1774951353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023104142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2405844023104142"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23206","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficiency of B-RAF-\/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23206"}}